Post-Marketing Surveillance of a generic Oxaliplatin (AlvoxalⓇ) in Iranian Patients with Cancer

• Principais autores: Farhad Shahi (Autor), Mojtaba Gorji, Assistant Professor of Pediatric Oncology (Autor), Mehrdad Payandeh, Assistant Professor of Hematology & Oncology (Autor), Hamid Rezvani, Associate Professor of Hematology & Oncology (Autor), Mohammad Vaezi, Associate Professor of Hematology & Oncology (Autor), Sharareh Seifi, Assistant Professor of Hematology & Oncology (Autor), Alireza Baari, Post doctoral fellowship (Autor), Reza Khalili-Dizaji, Post doctoral fellowship (Autor), Seyed Mehdi Hashemi, Associate Professor of Hematology & Oncology (Autor), Saeid Salimi, post doctoral fellowship (Autor), Hosein Kamranzadeh, Associate Professor of Hematology & Oncology (Autor), Babak Shazad, Post doctoral fellowship (Autor), Sina Salari, Associate Professor of Hematology & Oncology (Autor), Davoud Oulad Dameshghi, Assistant Professor of Hematology & Oncology (Autor), Mehdi Sarkheil, Post doctoral fellowship (Autor), Mehrzad Mirzania, Associate Professor of Hematology & Oncology (Autor), Nassim Anjidani, Pharm. D. (Autor)
• Formato: Livro
• Publicado em: Elsevier, 2022-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

ABSTRACT: Background: CRC is the second and third most common cancer in women and men, respectively. The national comprehensive cancer network guidelines recommend oxaliplatin-based chemotherapy as a preferred regimen for patients with advanced or metastatic colon cancer. Oxaliplatin is also used in...